Get the Stockscreener App
9.27
1.59%
-0.15
After Hours:
9.09
-0.18
-1.94%
Anteris Technologies Global Corp stock is traded at $9.27, with a volume of 1.06M.
It is down -1.59% in the last 24 hours and up +28.04% over the past month.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
See More
Previous Close:
$9.42
Open:
$9.3
24h Volume:
1.06M
Relative Volume:
1.02
Market Cap:
$902.36M
Revenue:
$1.85M
Net Income/Loss:
$-95.19M
P/E Ratio:
-4.1742
EPS:
-2.2208
Net Cash Flow:
$-86.88M
1W Performance:
-2.11%
1M Performance:
+28.04%
6M Performance:
+87.27%
1Y Performance:
+131.17%
1-Day Range:
$9.23
$9.59
1-Week Range:
$9.05
$9.86
52-Week Range:
$2.85
$10.14
Anteris Technologies Global Corp Stock (AVR) Company Profile
Name
Anteris Technologies Global Corp
Sector
Industry
Phone
651-493-0606
Address
860 BLUE GENTIAN ROAD, EAGAN
Compare AVR vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
9.27 | 916.96M | 1.85M | -95.19M | -86.88M | -2.2208 |
ISRG
Intuitive Surgical Inc
|
417.07 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.16 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.84 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.09 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
193.94 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-11-26 | Initiated | Wells Fargo | Overweight |
| Jan-08-25 | Initiated | Lake Street | Buy |
| Jan-07-25 | Initiated | Barclays | Overweight |
| Jan-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
View All
Anteris Technologies Global Corp Stock (AVR) Latest News
Anteris Technologies Global Corp. (AVR) Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical InvestmentCore Business Growth - newsline.com
Funds from operations of Anteris Technologies Global Corp. – NASDAQ:AVR - TradingView
Anteris Technologies (AVR) director exercises 17,580 RSUs into common shares - Stock Titan
Anteris (AVR) CFO exercises options, delivers 39,595 shares for taxes - Stock Titan
AVR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Anteris Technologies Global Corp. (AVR) Q1 2026 Earnings: EPS Misses Estimates Significantly Amid Continued R&D InvestmentGAAP Earnings Report - newsline.com
Anteris Technologies Secures French Regulatory Approval to Begin Paradigm Trial Recruitment; Shares Fall 6% - marketscreener.com
Update: Anteris Technologies Secures French Regulatory Approval to Begin Paradigm Trial Recruitment; Shares Fall 6% - Moomoo
Anteris Advances DurAVR Program Through ASX 300 Expansion - Kalkine Media
Anteris Technologies Global Corp Gets French Regulatory Clearance For Duravr Paradigm Global Pivotal Trial - TradingView
Anteris Wins French Clearance to Expand Global DurAVR Heart Valve Trial - TipRanks
France clearance marks key milestone for Anteris' pivotal PARADIGM Trial - Yahoo Finance
Anteris Technologies Secures French Regulatory Approval to Begin Paradigm Trial Recruitment - marketscreener.com
Anteris Technologies Global Corp. Receives French Regulatory Clearance for Duravr Transcatheter Heart Valve Global Pivotal Trial - marketscreener.com
Anteris Technologies Global Receives French Regulator's Approval for DurAVR Trial in Aortic Stenosis - marketscreener.com
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance - The Manila Times
Why Is Anteris Technologies (ASX: AVR) Trading Near a 52-Week High? - Kalkine
Insider Scoop: Major Director Buy Signals Fresh Confidence in Anteris Technologies Global Corp. - TipRanks
Anteris Director Susan Knight Buys First Stake in Company - TipRanks
Anteris Investors Shift From ASX CDIs to Nasdaq Common Stock in May - TipRanks
Anteris Technologies (AVR) director purchases 11,000 shares in open market - Stock Titan
Why Is Anteris Technologies Global Corp. (AVR) Stock Up Today? - Meyka
Anteris Options Lapse, Trimming Potential Future Dilution - TipRanks
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR) - The Globe and Mail
Anteris (NASDAQ: AVR) signs $250M at-the-market sales agreement with TD Cowen - Stock Titan
ChartWatch ASX scans: Brazilian Rare Earths, Echoiq, Weebit Nano, Anteris Technologies, Global X Semiconductor ETF - MSN
AVR - Finviz
Anteris Technologies Global Corp. Q1 2026 Earnings: EPS Misses Expectations as Stock RisesWeak Earnings Momentum - The Legal Advocate
Anteris launches $250m at-the-market program to fund structural heart push - TipRanks
Anteris Technologies Global Corp plans to issue up to $250 million in common stock through TD Cowen as the underwriter. - Bitget
Anteris Technologies Global Launches $250 Million ATM Offering Under Sales Agreement With TD Cowen - TradingView
Anteris (NASDAQ: AVR) launches $250M at-the-market share program - Stock Titan
Anteris Technologies (NASDAQ: AVR) establishes $250M ATM with TD Cowen - Stock Titan
Anteris Technologies Global Corp. (AVR) Q1 2026 Earnings: Pre-Revenue Biotech Posts Wider-Than-Expected Loss, Stock Rallies on Pipeline OptimismCash Flow Report - newsline.com
ChartWatch ASX Scans: Brazilian Rare Earths, Echoiq, Weebit Nano. Anteris Technologies, Global X Semiconductor ETF - Market Index
Anteris Technologies Global : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Director Susan Knight reports initial insider status at Anteris (NASDAQ: AVR) - Stock Titan
Number of shareholders of Anteris Technologies Global Corp. – NASDAQ:AVR - TradingView
Stephen Denaro details indirect Anteris (AVR) share and option holdings - Stock Titan
Nantahala holds 6,143,154 shares of Anteris (AVR) as of 03/31/2026 - Stock Titan
AVR Maintained by Barclays -- Price Target Raised to $18.00 - GuruFocus
We Think Anteris Technologies Global (ASX:AVR) Can Afford To Drive Business Growth - simplywall.st
Anteris Technologies Global Corp. (AVR) Gets a Buy from TD Cowen - The Globe and Mail
Anteris Announces Results for the First Quarter of 2026 - Sahm
Anteris Technologies Adds Experienced Financial Leaders to Board - The Globe and Mail
TradingKey - TradingKey
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation - Yahoo Finance
How Should Investors Value Anteris Technologies Global Corp (AVR - GuruFocus
Anteris Technologies appoints two directors to board - Investing.com
Anteris Technologies appoints two directors to board By Investing.com - Investing.com South Africa
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - The Manila Times
Anteris Technologies Global Corp Stock (AVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anteris Technologies Global Corp Stock (AVR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Knight Susan Elizabeth | Director |
Jun 02 '26 |
Buy |
9.29 |
11,000 |
102,228 |
11,000 |
| L1 Capital Pty Ltd | 10% Owner |
Jan 22 '26 |
Buy |
5.75 |
5,000,000 |
28,750,000 |
13,219,814 |
1.68%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):